{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:03:58Z","timestamp":1782882238550,"version":"3.54.5"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["899671-SPIOMET4HEALTH"],"award-info":[{"award-number":["899671-SPIOMET4HEALTH"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polycystic ovary syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affecting 5\u201310% of AYAs worldwide. There is no approved pharmacological therapy for PCOS. Standard off-label treatment with oral contraceptives (OCs) reverts neither the underlying pathophysiology nor the associated co-morbidities. Pilot studies have generated new insights into the pathogenesis of PCOS, leading to the development of a new treatment consisting of a fixed, low-dose combination of two so-called insulin sensitisers [pioglitazone (PIO), metformin (MET)] and one mixed anti-androgen and anti-mineralocorticoid also acting as an activator of brown adipose tissue [spironolactone (SPI)], within a single tablet (SPIOMET). The present trial will evaluate the efficacy, tolerability and safety of SPIOMET, on top of lifestyle measures, for the treatment of PCOS in AYAs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial, AYAs with PCOS will be recruited from 7 clinical centres across Europe. Intention is to randomise a total of 364 eligible patients into four arms (1:1:1:1): Placebo, PIO, SPI\u2009+\u2009PIO (SPIO) and SPI\u2009+\u2009PIO\u2009+\u2009MET (SPIOMET). Active treatment over 12\u00a0months will consist of lifestyle guidance plus the ingestion of one tablet daily (at dinner time); post-treatment follow-up will span 6\u00a0months. Primary endpoint is on- and post-treatment ovulation rate. Secondary endpoints are clinical features (hirsutism, menstrual regularity); endocrine-metabolic variables (androgens, lipids, insulin, inflammatory markers); epigenetic markers; imaging data (carotid intima-media thickness, body composition, abdominal fat partitioning, hepatic fat); safety profile; adherence, tolerability and acceptability of the medication; and quality of life in the study participants. Superiority (in this order) of SPIOMET, SPIO and PIO will be tested over placebo, and if present, subsequently the superiority of SPIOMET versus PIO, and if still present, finally versus SPIO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The present study will be the first to evaluate\u2014in a randomised, double-blind, placebo-controlled way\u2014the efficacy, tolerability and safety of SPIOMET treatment for early PCOS, on top of a lifestyle intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT 2021\u2013003177-58. Registered on 22 December 2021.<\/jats:p>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=%092021-003177-58\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=%092021-003177-58<\/jats:ext-link>.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07593-6","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:19:04Z","timestamp":1694776744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["SPIOMET4HEALTH\u2014efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Cristina","family":"Garcia-Beltran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Malpique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne S.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdevs","family":"Bas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Bassols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyza","family":"Darendeliler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Dieris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaminia","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Fr\u00f6hlich-Reiterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gambineri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Glintborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"L\u00f3pez-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f8nnaug","family":"\u00d8deg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille","family":"Ravn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reinehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Renzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Vanky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Vicente","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"de Zegher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4595-7191","authenticated-orcid":false,"given":"Lourdes","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"11","key":"7593_CR1","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/ijerph15112589","volume":"15","author":"WM Wolf","year":"2018","unstructured":"Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race\/ethnicity. Int J Environ Res Public Health. 2018;15(11):2589.","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"7593_CR2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/gye.16.6.443.446","volume":"16","author":"SR Davis","year":"2002","unstructured":"Davis SR, Knight S, White V, Claridge C, Davis BJ, Bell R. Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecol Endocrinol. 2002;16(6):443\u20136.","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"7593_CR3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000479371","volume":"88","author":"L Ib\u00e1\u00f1ez","year":"2017","unstructured":"Ib\u00e1\u00f1ez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary NS, Gambineri A, Garcia Rudaz C, Hoeger KM, L\u00f3pez-Bermejo A, Ong K, Pe\u00f1a AS, Reinehr T, Santoro N, Tena-Sempere M, Tao R, Yildiz BO, Alkhayyat H, Deeb A, Joel D, Horikawa R, de Zegher F, Lee PA. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017;88(6):371\u201395.","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"7593_CR4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12916-020-01516-x","volume":"18","author":"AS Pe\u00f1a","year":"2020","unstructured":"Pe\u00f1a AS, Witchel SF, Hoeger KM, Oberfield SE, Vogiatzi MG, Misso M, Garad R, Dabadghao P, Teede H. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 2020;18(1):72.","journal-title":"BMC Med"},{"issue":"4","key":"7593_CR5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/humupd\/dmy007","volume":"24","author":"NS Kakoly","year":"2018","unstructured":"Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018;24(4):455\u201367.","journal-title":"Hum Reprod Update"},{"issue":"6","key":"7593_CR6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/humrep\/deac050","volume":"37","author":"X Chen","year":"2022","unstructured":"Chen X, Gissler M, Lavebratt C. Association of maternal polycystic ovary syndrome and diabetes with preterm birth and offspring birth size: a population-based cohort study. Hum Reprod. 2022;37(6):1311\u201323.","journal-title":"Hum Reprod"},{"issue":"9","key":"7593_CR7","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/humrep\/deac154","volume":"37","author":"SQ Wei","year":"2022","unstructured":"Wei SQ, Bilodeau-Bertrand M, Auger N. Association of PCOS with offspring morbidity: a longitudinal cohort study. Hum Reprod. 2022;37(9):2135\u201342.","journal-title":"Hum Reprod"},{"issue":"6","key":"7593_CR8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.fertnstert.2020.12.018","volume":"115","author":"KJ Ryu","year":"2021","unstructured":"Ryu KJ, Kim MS, Kim HK, Kim YJ, Yi KW, Shin JH, Hur JY, Kim T, Park H. Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study. Fertil Steril. 2021;115(6):1569\u201375.","journal-title":"Fertil Steril"},{"issue":"1","key":"7593_CR9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1210\/clinem\/dgab658","volume":"107","author":"C Falzarano","year":"2022","unstructured":"Falzarano C, Lofton T, Osei-Ntansah A, Oliver T, Southward T, Stewart S, Andrisse S. Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome. J Clin Endocrinol Metab. 2022;107(1):258\u201372.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"7593_CR10","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/humrep\/dez104","volume":"34","author":"S Karthik","year":"2019","unstructured":"Karthik S, Vipin VP, Kapoor A, Tripathi A, Shukla M, Dabadghao P. Cardiovascular disease risk in the siblings of women with polycystic ovary syndrome. Hum Reprod. 2019;34(8):1559\u201366.","journal-title":"Hum Reprod"},{"issue":"1","key":"7593_CR11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2018.5188","volume":"5","author":"W Yin","year":"2019","unstructured":"Yin W, Falconer H, Yin L, Xu L, Ye W. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 2019;5(1):106\u20137.","journal-title":"JAMA Oncol"},{"issue":"12","key":"7593_CR12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.tem.2018.09.005","volume":"29","author":"F de Zegher","year":"2018","unstructured":"de Zegher F, L\u00f3pez-Bermejo A, Ib\u00e1\u00f1ez L. Central obesity, faster maturation, and \u201cPCOS\u201d in girls. Trends Endocrinol Metab. 2018;29(12):815\u20138.","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"7593_CR13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmed.2023.02.006","volume":"29","author":"L Ib\u00e1\u00f1ez","year":"2023","unstructured":"Ib\u00e1\u00f1ez L, de Zegher F. Adolescent PCOS: a postpubertal central obesity syndrome. Trends Mol Med. 2023;29(5):354\u201363.","journal-title":"Trends Mol Med"},{"issue":"4","key":"7593_CR14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jadohealth.2017.04.010","volume":"61","author":"L Ib\u00e1\u00f1ez","year":"2017","unstructured":"Ib\u00e1\u00f1ez L, Del R\u00edo L, D\u00edaz M, Sebastiani G, Pozo \u00d3J, L\u00f3pez-Bermejo A, de Zegher F. Normalizing ovulation rate by preferential reduction of hepato-visceral fat in adolescent girls with polycystic ovary syndrome. J Adolesc Health. 2017;61(4):446\u201353.","journal-title":"J Adolesc Health"},{"issue":"5","key":"7593_CR15","doi-asserted-by":"crossref","first-page":"bvaa032","DOI":"10.1210\/jendso\/bvaa032","volume":"4","author":"L Ib\u00e1\u00f1ez","year":"2020","unstructured":"Ib\u00e1\u00f1ez L, D\u00edaz M, Garc\u00eda-Beltr\u00e1n C, Malpique R, Garde E, L\u00f3pez-Bermejo A, de Zegher F. Toward a treatment normalizing ovulation rate in adolescent girls with polycystic ovary syndrome. J Endocr Soc. 2020;4(5):bvaa032.","journal-title":"J Endocr Soc"},{"issue":"1","key":"7593_CR16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/humrep\/dey343","volume":"34","author":"MA Brower","year":"2019","unstructured":"Brower MA, Hai Y, Jones MR, Guo X, Chen YI, Rotter JI, Krauss RM, Legro RS, Azziz R, Goodarzi MO. Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. Hum Reprod. 2019;34(1):127\u201336.","journal-title":"Hum Reprod"},{"issue":"9","key":"7593_CR17","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/oby.21935","volume":"25","author":"F de Zegher","year":"2017","unstructured":"de Zegher F, Reinehr T, Malpique R, Darendeliler F, L\u00f3pez-Bermejo A, Ib\u00e1\u00f1ez L. Reduced prenatal weight gain and\/or augmented postnatal weight gain precedes polycystic ovary syndrome in adolescent girls. Obesity (Silver Spring). 2017;25(9):1486\u20139.","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"7593_CR18","doi-asserted-by":"crossref","first-page":"e1007813","DOI":"10.1371\/journal.pgen.1007813","volume":"14","author":"F Day","year":"2018","unstructured":"Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, Kraft P, Lin N, Huang H, Broer L, Magi R, Saxena R, Laisk T, Urbanek M, Hayes MG, Thorleifsson G, Fernandez-Tajes J, Mahajan A, Mullin BH, Stuckey BGA, Spector TD, Wilson SG, Goodarzi MO, Davis L, Obermayer-Pietsch B, Uitterlinden AG, Anttila V, Neale BM, Jarvelin MR, Fauser B, Kowalska I, Visser JA, Andersen M, Ong K, Stener-Victorin E, Ehrmann D, Legro RS, Salumets A, McCarthy MI, Morin-Papunen L, Thorsteinsdottir U, Stefansson K, Styrkarsdottir U, Perry JRB, Dunaif A, Laven J, Franks S, Lindgren CM, Welt CK, 23andMe Research Team. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018;14(12):e1007813.","journal-title":"PLoS Genet"},{"issue":"12","key":"7593_CR19","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2018-00935","volume":"103","author":"E Nilsson","year":"2018","unstructured":"Nilsson E, Benrick A, Kokosar M, Krook A, Lindgren E, K\u00e4llman T, Martis MM, H\u00f8jlund K, Ling C, Stener-Victorin E. Transcriptional and epigenetic changes influencing skeletal muscle metabolism in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2018;103(12):4465\u201377.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7593_CR20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/cen.13913","volume":"90","author":"S Shorakae","year":"2019","unstructured":"Shorakae S, Jona E, de Courten B, Lambert GW, Lambert EA, Phillips SE, Clarke IJ, Teede HJ, Henry BA. Brown adipose tissue thermogenesis in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2019;90(3):425\u201332.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"7593_CR21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","volume":"10","author":"AE Joham","year":"2022","unstructured":"Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, Boyle J, Teede HJ. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668\u201380.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7593_CR22","doi-asserted-by":"crossref","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. International PCOS Network. recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;15:dgad463.","DOI":"10.1210\/clinem\/dgad463"},{"issue":"11","key":"7593_CR23","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4158\/EP15748.DSC","volume":"21","author":"NF Goodman","year":"2015","unstructured":"Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome\u2014Part 1. Endocr Pract. 2015;21(11):1291\u2013300.","journal-title":"Endocr Pract"},{"issue":"11","key":"7593_CR24","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/archdischild-2014-306471","volume":"100","author":"N Hecht Baldauff","year":"2015","unstructured":"Hecht Baldauff N, Arslanian S. Optimal management of polycystic ovary syndrome in adolescence. Arch Dis Child. 2015;100(11):1076\u201383.","journal-title":"Arch Dis Child"},{"issue":"8","key":"7593_CR25","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1210\/jc.2005-0628","volume":"90","author":"R Azziz","year":"2005","unstructured":"Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90(8):4650\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7593_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10815-016-0836-8","volume":"34","author":"B Hanson","year":"2017","unstructured":"Hanson B, Johnstone E, Dorais J, Silver B, Peterson CM, Hotalin J. Female infertility, infertility-associated diagnoses, and comorbidities: a review. J Assist Reprod Genet. 2017;34(2):167\u201377.","journal-title":"J Assist Reprod Genet"},{"issue":"5","key":"7593_CR27","doi-asserted-by":"crossref","first-page":"E902","DOI":"10.1210\/jc.2013-1041","volume":"98","author":"L Ib\u00e1\u00f1ez","year":"2013","unstructured":"Ib\u00e1\u00f1ez L, D\u00edaz M, Sebastiani G, Marcos MV, L\u00f3pez-Bermejo A, de Zegher F. Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity. J Clin Endocrinol Metab. 2013;98(5):E902\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7593_CR28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2265.2012.04466.x","volume":"78","author":"A Harmanci","year":"2013","unstructured":"Harmanci A, Cinar N, Bayraktar M, Yildiz BO. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2013;78(1):120\u20135.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"7593_CR29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.contraception.2012.07.005","volume":"87","author":"K Aydin","year":"2013","unstructured":"Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013;87(3):358\u201362.","journal-title":"Contraception"},{"issue":"12","key":"7593_CR30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMra1011035","volume":"371","author":"GI Shulman","year":"2014","unstructured":"Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(12):1131\u201341.","journal-title":"N Engl J Med"},{"issue":"23","key":"7593_CR31","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","volume":"377","author":"LS M\u00f8rch","year":"2017","unstructured":"M\u00f8rch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard \u00d8. Contemporary Hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228\u201339.","journal-title":"N Engl J Med"},{"issue":"4","key":"7593_CR32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bcp.12535","volume":"79","author":"L Andersen","year":"2015","unstructured":"Andersen L, Friis S, Hallas J, Ravn P, Kristensen BW, Gaist D. Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study. Br J Clin Pharmacol. 2015;79(4):677\u201384.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"7593_CR33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijgo.12455","volume":"141","author":"MV Dragoman","year":"2018","unstructured":"Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287\u201394.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"7593_CR34","doi-asserted-by":"crossref","first-page":"10182","DOI":"10.1038\/s41598-019-46644-4","volume":"9","author":"S Manzoor","year":"2019","unstructured":"Manzoor S, Ganie MA, Amin S, Shah ZA, Bhat IA, Yousuf SD, Jeelani H, Kawa IA, Fatima Q, Rashid F. Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with polycystic ovarian syndrome: an observational study. Sci Rep. 2019;9(1):10182.","journal-title":"Sci Rep"},{"issue":"8","key":"7593_CR35","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1210\/jcem.86.8.7756","volume":"86","author":"L Ib\u00e1\u00f1ez","year":"2001","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab. 2001;86(8):3595\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"7593_CR36","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1210\/jcem.87.6.8568","volume":"87","author":"L Ib\u00e1\u00f1ez","year":"2002","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Ferrer A, Ong K, Dunger DB, De Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab. 2002;87(6):2870\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7593_CR37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/humrep\/deg056","volume":"18","author":"L Ib\u00e1\u00f1ez","year":"2003","unstructured":"Ib\u00e1\u00f1ez L, de Zegher F. Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Hum Reprod. 2003;18(1):57\u201360.","journal-title":"Hum Reprod"},{"issue":"6","key":"7593_CR38","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1210\/jc.2002-022002","volume":"88","author":"L Ib\u00e1\u00f1ez","year":"2003","unstructured":"Ib\u00e1\u00f1ez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab. 2003;88(6):2600\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"7593_CR39","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1210\/jc.2004-0047","volume":"89","author":"L Ib\u00e1\u00f1ez","year":"2004","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Cabr\u00e9 S, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab. 2004;89(9):4716\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7593_CR40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jc.2004-1405","volume":"90","author":"L Ib\u00e1\u00f1ez","year":"2005","unstructured":"Ib\u00e1\u00f1ez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab. 2005;90(1):39\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7593_CR41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/humupd\/dmi054","volume":"12","author":"L Ib\u00e1\u00f1ez","year":"2006","unstructured":"Ib\u00e1\u00f1ez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update. 2006;12(3):243\u201352.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"7593_CR42","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/jc.2006-2684","volume":"92","author":"L Ib\u00e1\u00f1ez","year":"2007","unstructured":"Ib\u00e1\u00f1ez L, L\u00f3pez-Bermejo A, del Rio L, Enr\u00edquez G, Valls C, de Zegher F. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J Clin Endocrinol Metab. 2007;92(5):1710\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7593_CR43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2265.2008.03472.x","volume":"71","author":"L Ib\u00e1\u00f1ez","year":"2009","unstructured":"Ib\u00e1\u00f1ez L, L\u00f3pez-Bermejo A, D\u00edaz M, Enr\u00edquez G, del R\u00edo L, de Zegher F. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol (Oxf). 2009;71(3):351\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"7593_CR44","doi-asserted-by":"crossref","first-page":"e12500","DOI":"10.1111\/ijpo.12500","volume":"14","author":"R Malpique","year":"2019","unstructured":"Malpique R, S\u00e1nchez-Infantes D, Garcia-Beltran C, Taxer\u00e5s SD, L\u00f3pez-Bermejo A, de Zegher F, Ib\u00e1\u00f1ez L. Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - evidence from randomized clinical trials. Pediatr Obes. 2019;14(5):e12500.","journal-title":"Pediatr Obes"},{"issue":"3","key":"7593_CR45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/dom.13539","volume":"21","author":"M Thuzar","year":"2019","unstructured":"Thuzar M, Law WP, Dimeski G, Stowasser M, Ho KKY. Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled cross-over study. Diabetes Obes Metab. 2019;21(3):509\u201316.","journal-title":"Diabetes Obes Metab"},{"key":"7593_CR46","unstructured":"Ballester MR, Puntes M, Mart\u00ednez J. Coimbra J, Molina P, Gich I, Antonijoan M, Hidlago I, Torres R, Peris D, Ib\u00e1\u00f1ez L. Optimizing the formulation and the study design to assess the comparative bioavailability of a new film-coated tablets (combination of Spironolactone 50 mg, Pioglitazone 7.5 mg, and Metformin 850 mg) versus the same individual components in healthy women, under fed conditions. 2nd International Conference on Medicinal Chemistry & Drug Design and 2nd International Conference on Bio Equivalence & Bio Availability; Barcelona, 2019 (pp53 Abstract book)."},{"issue":"5","key":"7593_CR47","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5114\/aoms.2018.77561","volume":"14","author":"P Kawalec","year":"2018","unstructured":"Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125\u201336.","journal-title":"Arch Med Sci"},{"key":"7593_CR48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/CLEP.S145983","volume":"10","author":"K Hirasen","year":"2017","unstructured":"Hirasen K, Evans D, Maskew M, Sanne IM, Shearer K, Govathson C, Malete G, Kluberg SA, Fox MP. The right combination - treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg. South Africa Clin Epidemiol. 2017;10:17\u201329.","journal-title":"South Africa Clin Epidemiol"},{"key":"7593_CR49","unstructured":"Food and Drug Administration. Label information NDA n\u00b0 012151. Aldactone\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012151s075lbl.pdf\n."},{"issue":"3","key":"7593_CR50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40257-014-0078-4","volume":"15","author":"N Somani","year":"2014","unstructured":"Somani N, Turvy D. Hirsutism: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):247\u201366.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"7593_CR51","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2013-1040","volume":"98","author":"MA Ganie","year":"2013","unstructured":"Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, Mir FA, Taing S. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab. 2013;98(9):3599\u2013607.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7593_CR52","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bcp.13152","volume":"83","author":"IS Mackenzie","year":"2017","unstructured":"Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol. 2017;83(3):653\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"7593_CR53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00125-020-05281-7","volume":"64","author":"U White","year":"2021","unstructured":"White U, Fitch MD, Beyl RA, Hellerstein MK, Ravussin E. Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial. Diabetologia. 2021;64(1):159\u201367.","journal-title":"Diabetologia"},{"key":"7593_CR54","unstructured":"European Medicines Agency (EMA). European Public Assesment Report (EPAR). Competact\u00ae. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/competact#product-information-section\n."},{"issue":"4","key":"7593_CR55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00404-017-4480-z","volume":"296","author":"Y Xu","year":"2017","unstructured":"Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: a meta-analysis. Arch Gynecol Obstet. 2017;296(4):661\u201377.","journal-title":"Arch Gynecol Obstet"},{"issue":"7305","key":"7593_CR56","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi JH, Banks AS, Estall JL, Kajimura S, Bostr\u00f6m P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bl\u00fcher M, Griffin PR, Spiegelman BM. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature. 2010;466(7305):451\u20136.","journal-title":"Nature"},{"issue":"9","key":"7593_CR57","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/dme.14053","volume":"36","author":"REJ Ryder","year":"2019","unstructured":"Ryder REJ, DeFronzo RA. Pioglitazone: inexpensive; very effective at reducing HbA1c; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit. Diabet Med. 2019;36(9):1185\u20136.","journal-title":"Diabet Med"},{"key":"7593_CR58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13229-018-0241-5","volume":"9","author":"L Capano","year":"2018","unstructured":"Capano L, Dupuis A, Brian J, Mankad D, Genore L, Hastie Adams R, Smile S, Lui T, Odrobina D, Foster JA, Anagnostou E. A pilot dose finding study of pioglitazone in autistic children. Mol Autism. 2018;9:59.","journal-title":"Mol Autism"},{"issue":"7675","key":"7593_CR59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature24042","volume":"550","author":"JY Hsu","year":"2017","unstructured":"Hsu JY, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, Kutach A, Joo W, Gao Z, Fu D, To C, Mondal K, Li B, Kekatpure A, Wang M, Laird T, Horner G, Chan J, McEntee M, Lopez M, Lakshminarasimhan D, White A, Wang SP, Yao J, Yie J, Matern H, Solloway M, Haldankar R, Parsons T, Tang J, Shen WD, Alice Chen Y, Tian H, Allan BB. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature. 2017;550(7675):255\u20139.","journal-title":"Nature"},{"issue":"7795","key":"7593_CR60","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, Cimino I, Yang M, Welsh P, Virtue S, Goldspink DA, Miedzybrodzka EL, Konopka AR, Esponda RR, Huang JT, Tung YCL, Rodriguez-Cuenca S, Tomaz RA, Harding HP, Melvin A, Yeo GSH, Preiss D, Vidal-Puig A, Vallier L, Nair KS, Wareham NJ, Ron D, Gribble FM, Reimann F, Sattar N, Savage DB, Allan BB, O\u2019Rahilly S. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444\u20138.","journal-title":"Nature"},{"issue":"1","key":"7593_CR61","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41598-021-86317-9","volume":"11","author":"F de Zegher","year":"2021","unstructured":"de Zegher F, D\u00edaz M, Villarroya J, Cair\u00f3 M, L\u00f3pez-Bermejo A, Villarroya F, Ib\u00e1\u00f1ez L. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Sci Rep. 2021;11(1):7018.","journal-title":"Sci Rep"},{"issue":"1","key":"7593_CR62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"TE LaMoia","year":"2021","unstructured":"LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021;42(1):77\u201396.","journal-title":"Endocr Rev"},{"issue":"8","key":"7593_CR63","doi-asserted-by":"crossref","first-page":"111258","DOI":"10.1016\/j.celrep.2022.111258","volume":"40","author":"AB Klein","year":"2022","unstructured":"Klein AB, Nicolaisen TS, Johann K, Fritzen AM, Mathiesen CV, Gil C, Pilmark NS, Karstoft K, Blond MB, Quist JS, Seeley RJ, F\u00e6rch K, Lund J, Kleinert M, Clemmensen C. The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance. Cell Rep. 2022;40(8):111258.","journal-title":"Cell Rep"},{"issue":"5","key":"7593_CR64","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cmet.2023.03.014","volume":"35","author":"SY Zhang","year":"2023","unstructured":"Zhang SY, Bruce K, Danaei Z, Li RJW, Barros DR, Kuah R, Lim YM, Mariani LH, Cherney DZ, Chiu JFM, Reich HN, Lam TKT. Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. Cell Metab. 2023;35(5):875-886.e5.","journal-title":"Cell Metab"},{"key":"7593_CR65","unstructured":"European Medicines Agency (EMA). CPMP\/4082\/00. Referral for Metformin. 2001. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75\/319\/eec-amended-glucophage\/glucophage-forte\/risidon\/dianben-international-non-proprietary-name_en.pdf\n."},{"issue":"7","key":"7593_CR66","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/pedi.12220","volume":"16","author":"M D\u00edaz","year":"2015","unstructured":"D\u00edaz M, Bassols J, L\u00f3pez-Bermejo A, de Zegher F, Ib\u00e1\u00f1ez L. Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children. Pediatr Diabetes. 2015;16(7):538\u201345.","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"7593_CR67","doi-asserted-by":"crossref","first-page":"e20164285","DOI":"10.1542\/peds.2016-4285","volume":"140","author":"B Pastor-Villaescusa","year":"2017","unstructured":"Pastor-Villaescusa B, Ca\u00f1ete MD, Caballero-Villarraso J, Hoyos R, Latorre M, V\u00e1zquez-Cobela R, Plaza-D\u00edaz J, Maldonado J, Bueno G, Leis R, Gil \u00c1, Ca\u00f1ete R, Aguilera CM. Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial. Pediatrics. 2017;140(1):e20164285.","journal-title":"Pediatrics"},{"issue":"2","key":"7593_CR68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000479369","volume":"89","author":"F de Zegher","year":"2018","unstructured":"de Zegher F, Garc\u00eda Beltr\u00e1n C, L\u00f3pez-Bermejo A, Ib\u00e1\u00f1ez L. Metformin for rapidly maturing girls with central adiposity: less liver fat and slower bone maturation. Horm Res Paediatr. 2018;89(2):136\u201340.","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"7593_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","volume":"30","author":"S Palomba","year":"2009","unstructured":"Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30(1):1\u201350.","journal-title":"Endocr Rev"},{"issue":"19","key":"7593_CR70","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","volume":"321","author":"J Flory","year":"2019","unstructured":"Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926\u20137.","journal-title":"JAMA"},{"issue":"3","key":"7593_CR71","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MAJ.0b013e3182a562b7","volume":"349","author":"FJ Pasquel","year":"2015","unstructured":"Pasquel FJ, Klein R, Adigweme A, Hinedi Z, Coralli R, Pimentel JL, Umpierrez GE. Metformin-associated lactic acidosis. Am J Med Sci. 2015;349(3):263\u20137.","journal-title":"Am J Med Sci"},{"issue":"6","key":"7593_CR72","doi-asserted-by":"crossref","first-page":"e100379","DOI":"10.1371\/journal.pone.0100379","volume":"9","author":"Q Liu","year":"2014","unstructured":"Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS ONE. 2014;9(6):e100379.","journal-title":"PLoS ONE"},{"issue":"7244","key":"7593_CR73","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/bmj.320.7244.1240","volume":"320","author":"TJ Cole","year":"2000","unstructured":"Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320(7244):1240\u20133.","journal-title":"BMJ"},{"issue":"1","key":"7593_CR74","doi-asserted-by":"crossref","first-page":"e001035","DOI":"10.1136\/bmjdrc-2019-001035","volume":"8","author":"C Garc\u00eda-Beltran","year":"2020","unstructured":"Garc\u00eda-Beltran C, Cereijo R, Quesada-L\u00f3pez T, Malpique R, L\u00f3pez-Bermejo A, de Zegher F, Ib\u00e1\u00f1ez L, Villarroya F. Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization. BMJ Open Diabetes Res Care. 2020;8(1):e001035.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"7593_CR75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","volume":"45","author":"RL Walsky","year":"2005","unstructured":"Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005;45(1):68\u201378.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"7593_CR76","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrendo.2013.149","volume":"9","author":"T Reinehr","year":"2013","unstructured":"Reinehr T. Lifestyle intervention in childhood obesity: changes and challenges. Nat Rev Endocrinol. 2013;9(10):607\u201314.","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"7593_CR77","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/oby.2009.17","volume":"17","author":"T Reinehr","year":"2009","unstructured":"Reinehr T, Widhalm K, l\u2019Allemand D, Wiegand S, Wabitsch M, Holl RW, APV-Wiss STudy Group and German Competence Net Obesity. Two-year follow-up in 21,784 overweight children and adolescents with lifestyle intervention. Obesity (Silver Spring). 2009;17(6):1196\u20139.","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"7593_CR78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11920-017-0834-2","volume":"19","author":"LG Cooney","year":"2017","unstructured":"Cooney LG, Dokras A. Depression and anxiety in polycystic ovary syndrome: etiology and treatment. Curr Psychiatry Rep. 2017;19(11):83.","journal-title":"Curr Psychiatry Rep"},{"issue":"6","key":"7593_CR79","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/adc.2008.143594","volume":"94","author":"T Reinehr","year":"2009","unstructured":"Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child. 2009;94(6):437\u201342.","journal-title":"Arch Dis Child"},{"issue":"11","key":"7593_CR80","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1210\/jc.2011-1609","volume":"96","author":"N Lass","year":"2011","unstructured":"Lass N, Kleber M, Winkel K, Wunsch R, Reinehr T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab. 2011;96(11):3533\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"7593_CR81","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jadohealth.2016.12.025","volume":"60","author":"JS Hausmann","year":"2017","unstructured":"Hausmann JS, Touloumtzis C, White MT, Colbert JA, Gooding HC. Adolescent and young adult use of social media for health and its implications. J Adolesc Health. 2017;60(6):714\u20139.","journal-title":"J Adolesc Health"},{"key":"7593_CR82","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","volume":"21","author":"D Ferriman","year":"1961","unstructured":"Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"7593_CR83","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000375530","volume":"83","author":"SF Witchel","year":"2015","unstructured":"Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ib\u00e1\u00f1ez L, Pena A, Horikawa R, Gomez-Lobo V, Joel D, Tfayli H, Arslanian S, Dabadghao P, Garcia Rudaz C, Lee PA. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr. 2015;83(6):376\u201389.","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"7593_CR84","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.1984.tb04020.x","volume":"111","author":"BM Burke","year":"1984","unstructured":"Burke BM, Cunliffe WJ. The assessment of acne vulgaris\u2013the Leeds technique. Br J Dermatol. 1984;111(1):83\u201392.","journal-title":"Br J Dermatol"},{"issue":"7","key":"7593_CR85","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1210\/jc.2013-1381","volume":"98","author":"F Fanelli","year":"2013","unstructured":"Fanelli F, Gambineri A, Belluomo I, Repaci A, Di Lallo VD, Di Dalmazi G, Mezzullo M, Prontera O, Cuomo G, Zanotti L, Paccapelo A, Morselli-Labate AM, Pagotto U, Pasquali R. Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS\/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. J Clin Endocrinol Metab. 2013;98(7):3058\u201367.","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"7593_CR86","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMcp0800459","volume":"358","author":"JC Carel","year":"2008","unstructured":"Carel JC, L\u00e9ger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22):2366\u201377.","journal-title":"N Engl J Med"},{"issue":"6","key":"7593_CR87","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1067\/mob.2000.108020","volume":"183","author":"C Moran","year":"2000","unstructured":"Moran C, Azziz R, Carmina E, Dewailly D, Fruzzetti F, Iba\u00f1ez L, Knochenhauer ES, Marcondes JA, Mendonca BB, Pignatelli D, Pugeat M, Rohmer V, Speiser PW, Witchel SF. 21-hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol. 2000;183(6):1468\u201374.","journal-title":"Am J Obstet Gynecol"},{"key":"7593_CR88","doi-asserted-by":"crossref","unstructured":"American Diabetes Association; Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37 Suppl 1:S81\u2013S90.","DOI":"10.2337\/dc14-S081"},{"issue":"Suppl 27","key":"7593_CR89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/pedi.12773","volume":"19","author":"EJ Mayer-Davis","year":"2018","unstructured":"Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, Aschner P, Craig ME. ISPAD clinical practice consensus guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018;19(Suppl 27):7\u201319.","journal-title":"Pediatr Diabetes"},{"key":"7593_CR90","volume-title":"nQuery Advisor Version 7.0 User\u2019s Guide","author":"JD Elashoff","year":"2007","unstructured":"Elashoff JD. nQuery Advisor Version 7.0 User\u2019s Guide. Los Angeles, CA: Statistical Solutions Ltd.; 2007."},{"key":"7593_CR91","unstructured":"Dixon WJ, Massey FJ. Introduction to Statistical Analysis. 4th Edition.  New York: McGraw-Hill; 1983. p.385\u2013414"},{"key":"7593_CR92","unstructured":"O'Brien RG, Muller, KE. Unified power analysis for t-tests through multivariate hypotheses. In: LK Edwards, editor. Applied analysis of variance in behavioral science.\u00a0 New York: Marcel Dekker; 1993. p. 297\u2013344."},{"key":"7593_CR93","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1196\/annals.1384.022","volume":"1098","author":"BK Gandara","year":"2007","unstructured":"Gandara BK, Leresche L, Mancl L. Patterns of salivary estradiol and progesterone across the menstrual cycle. Ann N Y Acad Sci. 2007;1098:446\u201350.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"7593_CR94","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9378(83)90016-9","volume":"147","author":"JK Choe","year":"1983","unstructured":"Choe JK, Khan-Dawood FS, Dawood MY. Progesterone and estradiol in the saliva and plasma during the menstrual cycle. Am J Obstet Gynecol. 1983;147(5):557\u201362.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"7593_CR95","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.fertnstert.2010.06.015","volume":"95","author":"E Codner","year":"2011","unstructured":"Codner E, Villarroel C, Eyzaguirre FC, L\u00f3pez P, Merino PM, P\u00e9rez-Bravo F, I\u00f1iguez G, Cassorla F. Polycystic ovarian morphology in postmenarchal adolescents. Fertil Steril. 2011;95(2):702-6.e1-2.","journal-title":"Fertil Steril"},{"issue":"1","key":"7593_CR96","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.fertnstert.2010.10.041","volume":"95","author":"E Codner","year":"2011","unstructured":"Codner E, Eyzaguirre FC, I\u00f1iguez G, L\u00f3pez P, P\u00e9rez-Bravo F, Torrealba IM, Cassorla F. Chilean Group for the Study of Ovarian Function in Type 1 Diabetes. Ovulation rate in adolescents with type 1 diabetes mellitus. Fertil Steril. 2011;95(1):197-202.e1.","journal-title":"Fertil Steril"},{"issue":"4","key":"7593_CR97","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1210\/jc.2012-3537","volume":"98","author":"A Gambineri","year":"2013","unstructured":"Gambineri A, Fanelli F, Prontera O, Repaci A, Di Dalmazi G, Zanotti L, Pagotto U, Flacco ME, Guidi J, Fava GA, Manzoli L, Pasquali R. Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on Italian high-school students. J Clin Endocrinol Metab. 2013;98(4):1641\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"7593_CR98","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1515\/CCLM.2010.303","volume":"48","author":"OA Mojiminiyi","year":"2010","unstructured":"Mojiminiyi OA, Abdella NA. Effect of homeostasis model assessment computational method on the definition and associations of insulin resistance. Clin Chem Lab Med. 2010;48(11):1629\u201334.","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"7593_CR99","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2007-1549","volume":"92","author":"KE Salley","year":"2007","unstructured":"Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome\u2013a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92(12):4546\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"7593_CR100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41390-019-0633-z","volume":"87","author":"M D\u00edaz","year":"2020","unstructured":"D\u00edaz M, Campderr\u00f3s L, Guimaraes MP, L\u00f3pez-Bermejo A, de Zegher F, Villarroya F, Ib\u00e1\u00f1ez L. Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal growth and adiposity measurements. Pediatr Res. 2020;87(5):897\u2013902.","journal-title":"Pediatr Res"},{"issue":"3","key":"7593_CR101","doi-asserted-by":"crossref","first-page":"dgz204","DOI":"10.1210\/clinem\/dgz204","volume":"105","author":"M D\u00edaz","year":"2020","unstructured":"D\u00edaz M, Bassols J, L\u00f3pez-Bermejo A, de Zegher F, Ib\u00e1\u00f1ez L. Low circulating levels of miR-451a in girls with polycystic ovary syndrome: different effects of randomized treatments. J Clin Endocrinol Metab. 2020;105(3):dgz204.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7593_CR102","first-page":"88","volume":"5","author":"I Moor","year":"2020","unstructured":"Moor I, Winter K, Bilz L, Bucksch J, Finne E, John N, Kolip P, Paulsen L, Ravens-Sieberer U, Schlattmann M, Sudeck G, Brindley C, Kaman A, Richter M. The 2017\/18 Health Behaviour in School-aged Children (HBSC) study - Methodology of the World Health Organization\u2019s child and adolescent health study. J Health Monit. 2020;5(3):88\u2013102.","journal-title":"J Health Monit"},{"issue":"9","key":"7593_CR103","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/obr.12866","volume":"20","author":"H Jebeile","year":"2019","unstructured":"Jebeile H, Gow ML, Baur LA, Garnett SP, Paxton SJ, Lister NB. Treatment of obesity, with a dietary component, and eating disorder risk in children and adolescents: A systematic review with meta-analysis. Obes Rev. 2019;20(9):1287\u201398.","journal-title":"Obes Rev"},{"key":"7593_CR104","unstructured":"Fairburn CG, Cooper Z, O\u2019Connor ME. Eating Disorder Examination Questionnaire. In: Fairburn CG, editor. Edition 16.0D. 2008."},{"issue":"2","key":"7593_CR105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijpharm.2014.03.057","volume":"469","author":"P Kozarewicz","year":"2014","unstructured":"Kozarewicz P. Regulatory perspectives on acceptability testing of dosage forms in children. Int J Pharm. 2014;469(2):245\u20138.","journal-title":"Int J Pharm"},{"key":"7593_CR106","unstructured":"Committee for Medicinal Products for Human Use (CHMP). CPMP\/ICH\/363\/96. ICH E9 Statistical Principles for Clinical Trials. 1998. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf\n."},{"key":"7593_CR107","unstructured":"Committee for Medicinal Products for Human Use (CHMP). EMA\/CHMP\/ICH\/436221\/2017 ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf\n."},{"key":"7593_CR108","unstructured":"SAS version 9.4 software, SAS Institute Inc. Cary, NC. https:\/\/www.sas.com\/es_es\/home.html\n."},{"issue":"3","key":"7593_CR109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpag.2019.02.119","volume":"32","author":"LJ Carlson","year":"2019","unstructured":"Carlson LJ, Shaw ND. Development of ovulatory menstrual cycles in adolescent girls. J Pediatr Adolesc Gynecol. 2019;32(3):249\u201353.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"7593_CR110","unstructured":"Food and Drug Administration (FDA). Guidance for industry. Computerized systems used in clinical investigations (2007). https:\/\/www.fda.gov\/media\/70970\/download\n."},{"key":"7593_CR111","unstructured":"Committee for Medicinal Products for Human Use (CHMP) from the European Medicines Evaluation Agency. EMA\/CPMP\/EWP\/1776\/99 Rev. 1. Guideline on Missing Data in Confirmatory Clinical Trials (2010). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-missing-data-confirmatory-clinical-trials_en.pdf\n."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07593-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T22:22:13Z","timestamp":1700346133000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07593-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7593"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07593-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be conducted in accordance with International Conference on Harmonisation Good Clinical Practice. The study has already obtained the full approval from all EC and National Competent Authorities. Written informed consent to participate will be obtained from participants or their parents (in case of minor participants).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"The model consent form and other related documentation given to participants will be provided on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"The universities of Barcelona and Leuven are joint holders of patents related to SPIOMET treatment of PCOS. The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"589"}}